[Benefits and risks of cyclooxygenase-2-selective inhibitor nonsteroidal antiinflammatory drugs].
Vallano
Antonio
A
Fundació Institut Català de Farmacologia. Servei de Farmacologia Clínica. Hospital Universitari Vall d'Hebron. Universitat Autònoma de Barcelona. Barcelona. España.
Llop
Roser
R
Bosch
Montserrat
M
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D007674:Kidney Diseases / Q000139:chemically induced; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D012871:Skin Diseases / Q000139:chemically induced
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases